Lesson plan

Efungumab

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody. As such, it "grabs" onto fungal hsp90, hence its proposed trade name. Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.

Back to article

Article summary

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody. As such, it "grabs" onto fungal hsp90, hence its proposed trade name. Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.